Evidence map›Paper›PMID 36281472›Full record

Trial reportCancer medicine2023

Clustering on longitudinal quality-of-life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial.

Jiahui Zhang, Weili Kong, Pingzhao Hu, Derek Jonker, Malcolm Moore, Jolie Ringash, Jeremy Shapiro, John Zalcberg, John Simes, Dongsheng Tu and 3 more

Open access · goldFull text readRandomized Controlled Trial
In one paragraph

Trial report in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 3 countries.

Jiahui ZhangDalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0001-6124-2175
Weili KongDepartment of Otolaryngology, Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.
Pingzhao HuDalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Derek JonkerOttawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
Malcolm MooreDepartment of Medicine and Pharmacology, University of Toronto, Toronto, Ontario, Canada.
Jolie RingashDepartment of Radiation Oncology, The Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Jeremy ShapiroCabrini Hospital and Monash University, Melbourne, Victoria, Australia.
John ZalcbergPeter MacCallum Cancer Centre and University of Melbourne.
John SimesNHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.
Dongsheng TuCanadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada.
Chris J O'CallaghanCanadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada.
Geoffrey LiuDalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Wei XuDalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
University of Toronto · CAQueen's University · CACabrini Hospital · AUPrincess Margaret Cancer Centre · CASichuan University · CNThe University of Melbourne · AUThe University of Sydney · AUUniversity of Ottawa · CAWestern University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAnalyzing longitudinal cancer quality-of-life (QoL) measurements and their impact on clinical outcomes may improve our understanding of patient trajectories during systemic therapy. We applied an unsupervised growth mixture modeling (GMM) approach to identify unobserved subpopulations ("patient clusters") in the CO.20 clinical trial longitudinal QoL data. Classes were then evaluated for differences in clinico-epidemiologic characteristics and overall survival (OS). METHODS AND MATERIALS: In CO.20, 750 chemotherapy-refractory metastatic colorectal cancer (CRC) patients were randomized to receive Brivanib+Cetuximab (n = 376, experimental arm) versus Cetuximab+Placebo (n = 374, standard arm) for 16 weeks. EORTC-QLQ-C30 QoL summary scores were calculated for each patient at seven time points, and GMM was applied to identify patient clusters (termed "classes"). Log-rank/Kaplan-Meier and multivariable Cox regression analyses were conducted to analyze the survival performance between classes. Cox analyses were used to explore the relationship between baseline QoL, individual slope, and the quadratic terms from the GMM output with OS.

resultsIn univariable analysis, the linear mixed effect model (LMM) identified sex and ECOG Performance Status as strongly associated with the longitudinal QoL score (p < 0.01). The patients within each treatment arm were clustered into three distinct QoL-based classes by GMM, respectively. The three classes identified in the experimental (log-rank p-value = 0.00058) and in the control arms (p < 0.0001) each showed significantly different survival performance. The GMM's baseline, slope, and quadratic terms were each significantly associated with OS (p < 0.001).

conclusionGMM can be used to analyze longitudinal QoL data in cancer studies, by identifying unobserved subpopulations (patient clusters). As demonstrated by CO.20 data, these classes can have important implications, including clinical prognostication.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsQuality of LifeCetuximabCluster AnalysisHumansCetuximabcancer treatmentclusteringgrowth mixture modelquality of lifesurvival analysis

Identifiers

PMID36281472
PMCPMC10028035
OpenAlexW4307228966

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read21
identifiers read1
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.